pl
en
Country
pl
Language
en
Janssen.tv Janssen.tv MENU

New treatment perspectives for CLL patients with del17p.

Speciality: Hematology, Oncology
Language : Polski
Broadcast type : Live conference
Duration : 00:13:30
Date: December 20, 2017

New Drug Program - Ibrutinib in the treatment of patients with chronic lymphocytic leukemia allows to change the perspective on high-risk CLL therapy.

Lecturers

Prof. Krzysztof Giannopoulos, MD, Ph.D
Internal medicine, Hematology Prof. Krzysztof Giannopoulos, MD, Ph.D Poland Head of the Department of Experimental Hematooncology at the Medical University of Lublin

Other in: Hematology

Clinical needs of patients with CLL in Poland.
Hematology Live conference Clinical needs of patients with CLL in Poland. Prof. Krzysztof Jamroziak, MD, Ph.D
PL
International standards - CLL treatment in the era of targeted therapies.
Hematology Live conference International standards - CLL treatment in the era of targeted therapies. Prof. Tadeusz Robak, Ph.D
PL
How to make the best use of treatment options within ibrutinib drug program?
Hematology Live conference How to make the best use of treatment options within ibrutinib drug program? Marek Dudziński, MD
PL
Program lekowy Ibrutynib w leczeniu chorych na PBL jako świadczenie gwarantowane cz. 1
Hematology Test transmission Program lekowy Ibrutynib w leczeniu chorych na PBL jako świadczenie gwarantowane cz. 1 Anna Banaszewska, MA
PL
Program lekowy Ibrutynib w leczeniu chorych na PBL jako świadczenie gwarantowane cz. 2
Hematology Live conference Program lekowy Ibrutynib w leczeniu chorych na PBL jako świadczenie gwarantowane cz. 2 Anna Banaszewska, MA
PL
Program lekowy Ibrutynib w leczeniu chorych na PBL jako świadczenie gwarantowane cz. 3
Hematology Live conference Program lekowy Ibrutynib w leczeniu chorych na PBL jako świadczenie gwarantowane cz. 3 Anna Banaszewska, MA
PL
Znaczenie rokownicze delecji i/lub mutacji genu TP53 w przewlekłej białaczce limfocytowej
Hematology Live conference Znaczenie rokownicze delecji i/lub mutacji genu TP53 w przewlekłej białaczce limfocytowej Bartosz Puła, MD, Ph.D
PL
Ocena statusu mutacji TP53 u chorych na przewlekłą białaczkę limfocytową wg wytycznych ERIC (European Research Initiative on CLL)
Hematology Live conference Ocena statusu mutacji TP53 u chorych na przewlekłą białaczkę limfocytową wg wytycznych ERIC (European Research Initiative on CLL) Tomasz Stokłosa, MD, Ph.D
PL
Możliwości leczenia chorych na przewlekłą białaczkę limfocytową z delecją lub/i mutacją genu TP53 w Polsce
Hematology Live conference Możliwości leczenia chorych na przewlekłą białaczkę limfocytową z delecją lub/i mutacją genu TP53 w Polsce Prof. Krzysztof Jamroziak, MD, Ph.D
PL
Ibrutinib in treatment of patients with chronic lymphocyte leukemia
Hematology Live conference Ibrutinib in treatment of patients with chronic lymphocyte leukemia Prof. Wiesław Jędrzejczak, MD, Ph.D
PL
New treatment perspectives for CLL patients with del17p
Hematology New treatment perspectives for CLL patients with del17p Prof. Tadeusz Robak, Ph.D
PL
New treatment perspectives for CLL patients with del17p
Hematology New treatment perspectives for CLL patients with del17p Prof. Tadeusz Robak, Ph.D
PL
New treatment perspectives for CLL patients with del17p
Hematology New treatment perspectives for CLL patients with del17p Prof. Tadeusz Robak, Ph.D
PL
Central European Hematology Forum
Hematology Live conference Central European Hematology Forum Several lecturers
EN
The growing need of Real World Data based on Imbruvica® case
Hematology, Oncology The growing need of Real World Data based on Imbruvica® case Several lecturers
PL
Ibrutinib: From stalemate to checkmate in difficult CLL cases
Hematology Ibrutinib: From stalemate to checkmate in difficult CLL cases Prof. Iwona Hus, MD, Ph.D
Prof. Tomasz Wróbel, MD, Ph.D
dr Kostas Stamatopoulos
PL
EN
Imbruvica® – new era in CLL and MCL Treatment
Hematology Imbruvica® – new era in CLL and MCL Treatment Prof. Vincent Lévy
EN
Imbruvica® – new era in CLL and MCL Treatment
Hematology Imbruvica® – new era in CLL and MCL Treatment Prof. Krzysztof Jamroziak, MD, Ph.D
PL
Imbruvica® – new era in CLL and MCL Treatment
Hematology Imbruvica® – new era in CLL and MCL Treatment Prof. Wojciech Jurczak
PL
Debate: Bortezomib induction treatment in MM prior ASCT- practice in accordance with standards
Hematology Open broadcast Debate: Bortezomib induction treatment in MM prior ASCT- practice in accordance with standards Prof. Krzysztof Giannopoulos, MD, Ph.D
Dominik Dytfeld, MD, Ph.D
Prof. Maria Bieniaszewska, MD, Ph.D
PL
DEBATE: How to optimally treat multiple myeloma patients with bortezomib?
Hematology Open broadcast DEBATE: How to optimally treat multiple myeloma patients with bortezomib? Prof. Iwona Hus, MD, Ph.D
Prof. Anna Dmoszyńska, MD, Ph.D
Sebastian Grosicki, MD, Ph.D
PL
Multiple Myeloma: world’s treatment standards, polish guidelines and their practical implications
Hematology Open broadcast Multiple Myeloma: world’s treatment standards, polish guidelines and their practical implications Prof. Lidia Usnarska-Zubkiewicz, MD, Ph.D
Prof. Wiesław Jędrzejczak, MD, Ph.D
Prof. Krzysztof Jamroziak, MD, Ph.D
PL
XXV Zjazdu PTHiT (Poznań) - Sesja satelitarna firmy Janssen
Hematology XXV Zjazdu PTHiT (Poznań) - Sesja satelitarna firmy Janssen Lekarz 1, Ph.D
PL

Other in: Oncology

Metastatic Prostate Cancer
Oncology Metastatic Prostate Cancer Prof. Piotr Wysocki
Prof. Heather Payne
dr Stefan Hinz
EN
1
PL
Plenary session IV - Regional Aspects of the Management of Advanced Prostate Cancer – Realities and Best Practice Sharing
Oncology, Urology Plenary session IV - Regional Aspects of the Management of Advanced Prostate Cancer – Realities and Best Practice Sharing Several lecturers
EN
Plenary session III - Advanced prostate cancer management now and in the future: what are the options? Recommended
Oncology Plenary session III - Advanced prostate cancer management now and in the future: what are the options? Iwona Skoneczna, MD, Ph.D
Prof. Robert Jones, Ph.D
Laurenţia Nicoleta Galeş, MD, Ph.D
EN
The growing need of Real World Data based on Imbruvica® case
Hematology, Oncology The growing need of Real World Data based on Imbruvica® case Several lecturers
PL
How to teach an old dog new tricks – treatment of mCRPC
Oncology How to teach an old dog new tricks – treatment of mCRPC Tomasz Borkowski, MD, Ph.D
Roman Sosnowski, MD, Ph.D
Prof. Piotr Wysocki
PL
The sooner the better? Evolution of disease and choice of therapy in systemic treatment of prostate cancer
Oncology The sooner the better? Evolution of disease and choice of therapy in systemic treatment of prostate cancer Prof. Piotr Wysocki
Iwona Skoneczna, MD, Ph.D
PL
When CRPC becomes a challenge. Urologist and Oncologist Aproach - Strong Together
Oncology When CRPC becomes a challenge. Urologist and Oncologist Aproach - Strong Together Jakub Dobruch, MD, Ph.D
Iwona Skoneczna, MD, Ph.D
PL
Czy są kontrowersje w leczeniu raka jajnika? - debata ekspertów.
Gynecology, Oncology Czy są kontrowersje w leczeniu raka jajnika? - debata ekspertów. Lt Col. Lubomir Bodnar, MD, Ph.D
Prof. Ewa Nowak-Markwitz, MD, Ph.D
PL
Assessment of disease progression in patients with castration-resistant prostate cancer
Oncology Assessment of disease progression in patients with castration-resistant prostate cancer Elżbieta Senkus-Konefka, MD, Ph.D
PL
Is a patient with oligometastases a candidate for surgical treatment?
Oncology Is a patient with oligometastases a candidate for surgical treatment? Roman Sosnowski, MD, Ph.D
PL
What is the role of modern hormone therapy in the treatment of advanced cancer and CRPC?
Oncology What is the role of modern hormone therapy in the treatment of advanced cancer and CRPC? Tomasz Borkowski, MD, Ph.D
PL
Which patients should continue receiving hormone treatment and which ones should start chemotherapy?
Oncology Which patients should continue receiving hormone treatment and which ones should start chemotherapy? Jakub Żołnierek, MD, Ph.D
PL
Advanced Prostate Cancer: To what stage of surgical treatment it is justified and when to start treatment at the earliest system?
Oncology Advanced Prostate Cancer: To what stage of surgical treatment it is justified and when to start treatment at the earliest system? Prof. Marcin Słojewski
PL
Defining progression in bones. Diagnostic imaging
Oncology Defining progression in bones. Diagnostic imaging Elżbieta Senkus-Konefka, MD, Ph.D
PL
Introduction – epidemiology and strategy of procedure
Oncology Introduction – epidemiology and strategy of procedure Prof. Maciej Krzakowski, MD, Ph.D
PL
Pathomorphological diagnostics and identification of castration resistance
Oncology Pathomorphological diagnostics and identification of castration resistance Marcin Ligaj, MD
PL
Molecular mechanisms of CRPC development
Oncology Molecular mechanisms of CRPC development Prof. Piotr Wysocki
PL
Systemic treatment of CRPC patients
Oncology Systemic treatment of CRPC patients Jakub Żołnierek, MD, Ph.D
PL
Advanced prostate cancer. The role of radiotherapy
Oncology Advanced prostate cancer. The role of radiotherapy Elżbieta Senkus-Konefka, MD, Ph.D
PL
Treatment of CRPC patients with abiraterone acetate within the National Health Fund's medication program
Oncology Treatment of CRPC patients with abiraterone acetate within the National Health Fund's medication program Prof. Piotr Wysocki
PL
How to effectively implement multidisciplinary treatment in practice
Oncology How to effectively implement multidisciplinary treatment in practice Tomasz Borkowski, MD, Ph.D
PL
Treating cancer pain
Oncology Treating cancer pain Aleksandra Ciałkowska-Rysz, MD, Ph.D
PL
The role of a psycho-oncologist in the treatment process
Oncology The role of a psycho-oncologist in the treatment process Mariola Kosowicz, MD, Ph.D
PL
Abiraterone acetate - a new drug in mCRPC therapy available in the medication program
Oncology Abiraterone acetate - a new drug in mCRPC therapy available in the medication program Prof. Piotr Wysocki
PL